Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

S7656

Sigma-Aldrich

Anti-Staphylococcal Enterotoxin A antibody produced in rabbit

whole antiserum

Synonym(s):

Anti-Ent A

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

MDL number:
MFCD00082016
UNSPSC Code:
12352203
NACRES:
NA.46

biological source

rabbit

Quality Level

200

conjugate

unconjugated

antibody form

whole antiserum

antibody product type

primary antibodies

clone

polyclonal

contains

15 mM sodium azide

species reactivity

Staphylococcus aureus

technique(s)

dot blot: 1:20,000 using using purified Staphyloccal Enterotoxin A immobilized on nitrocellulose membranes (protein concentation: 50 ng/dot).
indirect ELISA: 1:20,000 using using Staphylococcal enterotoxin A

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

General description

The antibody is positive against Staphylococcal enterotoxin A, negative versus Staphylococcal enterotoxin B, Cholera toxin, and Pseudomonas exotoxin A (protein concentration: 50-500 ng/dot). The antibody has not been tested for neutralization potency against active Staphylococcal enterotoxin A.

Immunogen

enterotoxin A from Staphylococcus aureus.

Application

Anti-Staphylococcal Enterotoxin A antibody has been used in western blotting, and enterotoxin A detection by ELISA (enzyme-linked immunosorbent assay).
Anti-Staphylococcal Enterotoxin A antibody produced in rabbit was used as a control to SEA-conjugated MUSE11 antibody produced in xenografted SCID mice.

Biochem/physiol Actions

Staphylococcal enterotoxin A (SEA) from Staphylococcal aureus is leading agent that causes of food poisoning. A concentration of as little as 0.5 mg/ml is sufficient to result in nausea, vomiting, diarrhea and cramps. It stimulates the cell proliferation of peripheral lymphocytes, induces the production of interferons and is important for gut immunity against S. aureus infections.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 1

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Sulfuric acid 99.999%

Sigma-Aldrich

339741

Sulfuric acid

Molecular Screening of Staphylococcal Enterotoxin Type A Encoding Gene from MRS Clinical Isolates
Hussein H A, et al.
American Journal of Microbiological Research, 4(2), 68-72 (2016)
M Shinoda et al.
Cancer research, 58(13), 2838-2843 (1998-07-14)
To reinforce cytotoxic activity and the targeting ability of lymphokine-activated killer cells with a T-cell phenotype (T-LAK) for adoptive immunotherapy against human bile duct carcinoma (BDC), staphylococcal enterotoxin A (SEA) was conjugated chemically with MUSE11 monoclonal antibody (MUSE11 mAb), directed
N Sakurai et al.
Biochemical and biophysical research communications, 256(1), 223-230 (1999-03-06)
A SEA-antibody single chain Fv (SEA-scFv) fusion protein was produced by bacterial expression system in this study. SEA-scFv has both staphylococcal enterotoxin A (SEA) effects and antibody activity directed at the epithelial mucin core protein MUC1, a cancer associated antigen.
A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma
Takemura S I, et al.
Cancer Immunology, Immunotherapy, 51(1), 33-44 (2002)
Shin-ichi Takemura et al.
Cancer immunology, immunotherapy : CII, 51(1), 33-44 (2002-02-15)
In cancer immunotherapy research, many bispecific antibodies (BsAbs) have been developed for directing T cells toward tumor cells. Recent advances in genetic engineering have made it possible to prepare immunoglobulin fragments consisting of variable domains using bacterial expression systems. Therefore
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service